GSK PLC Sponsored ADR (NYSE:GSK) Receives $37.38 Average Price Target from Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been assigned a consensus recommendation of “Reduce” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $37.3750.

A number of research analysts have recently commented on the stock. Berenberg Bank restated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Sunday, August 3rd. Finally, Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a report on Monday, April 28th.

GSK Trading Up 0.2%

NYSE GSK opened at $40.1450 on Wednesday. The company’s 50-day moving average price is $38.34 and its 200-day moving average price is $38.13. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The stock has a market cap of $81.77 billion, a PE ratio of 18.59, a PEG ratio of 1.74 and a beta of 0.51. GSK has a 12 month low of $31.72 and a 12 month high of $44.67.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts forecast that GSK will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK’s dividend payout ratio is presently 77.78%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dodge & Cox grew its holdings in GSK by 14.9% during the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock worth $3,046,972,000 after acquiring an additional 10,210,921 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of GSK by 4.4% during the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after buying an additional 1,306,590 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after buying an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of GSK by 2.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after buying an additional 155,392 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of GSK by 5.7% in the 1st quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock valued at $293,692,000 after purchasing an additional 411,869 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.